Search results for "net survival"

showing 9 items of 19 documents

Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical …

2022

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of malignancies derived from neuroendocrine cells that can occur anywhere along the gastrointestinal tract. GEP-NETs incidence has been steadily increasing over the past decades, in parallel with the increasing incidence of the metabolic syndrome (MetS). It is not yet fully known whether the MetS components (such as obesity, dyslipidemia and type 2 diabetes) could be involved in the etiology of GEP-NETs or could influence their outcomes. In this review, a panel of experts of the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Endocrinology…

ConsensusSettore MED/06 - Oncologia MedicaGEP-NET progressionMetabolic disordersHematologyMedical OncologyMetabolic syndromeNOGEP-NET survivalPancreatic NeoplasmsNeuroendocrine Tumorsgastroenteropancreatic neuroendocrine tumors; gep-net progression; gep-net survival; metabolic disorders; metabolic syndrome; consensus; humans; medical oncology; diabetes mellitus; type 2; intestinal neoplasms; neuroendocrine tumors; pancreatic neoplasms; stomach neoplasmsOncologyGEP-NET progression; GEP-NET survival; Gastroenteropancreatic neuroendocrine tumors; Metabolic disorders; Metabolic syndromeDiabetes Mellitus Type 2Stomach NeoplasmsIntestinal NeoplasmsDiabetes MellitusHumansLS4_3Gastroenteropancreatic neuroendocrine tumorsType 2
researchProduct

Trends in net survival from stomach cancer in six European Latin countries: results from the SUDCAN population-based study

2016

IF 2.415; International audience; Gastric cancers are a clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from gastric cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and explore the trends in net survival and in the dynamics of the excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. The results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 200…

MaleCancer ResearchDatabases FactualEpidemiology0302 clinical medicineBelgiumEpidemiologyRegistries030212 general & internal medicineYoung adultStomach cancerNet SurvivalAged 80 and overstomach cancerMiddle Aged3. Good healthSurvival RateEuropeTrend analysisItalyOncologyPopulation Surveillance030220 oncology & carcinogenesisFemaleFrancenet survivalSwitzerlandAdultmedicine.medical_specialtyAdolescent[SDV.CAN]Life Sciences [q-bio]/CancerYoung Adult03 medical and health sciencesStomach NeoplasmsmedicineHumansSurvival rateexcess mortality rateAgedPortugalbusiness.industryCarcinomaPublic Health Environmental and Occupational HealthCancermedicine.diseaseEstrogenPopulation based studyGastric-cancerSpaincancer registriesSurgerytrend analysisbusinessDemography
researchProduct

Trends in net survival from colon cancer in six European Latin countries: results from the SUDCAN population-based study.

2016

IF 2.415; International audience; Colon cancer represents a major public health issue. The aim of the SUDCAN collaborative study was to compare the net survival from colon cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) and provide trends in net survival and dynamics of the excess mortality rates up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results were reported from 1992 to 2004 in France, Italy, Spain, and Switzerland and from 2000 to 2004 …

MaleCancer ResearchDatabases FactualEpidemiologyColorectal cancer[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineBelgiumEpidemiologyRegistries030212 general & internal medicineYoung adultNet SurvivalAged 80 and overMiddle Aged3. Good healthSurvival RateEuropeTrend analysisGeographyItalyOncologycolon cancerPopulation Surveillance030220 oncology & carcinogenesisColonic NeoplasmsFemaleFrancenet survivalSwitzerlandAdultmedicine.medical_specialtyAdolescent[SDV.CAN]Life Sciences [q-bio]/CancerColorectal-CancerYoung Adult03 medical and health sciencesmedicineHumansMortalitySurvival rateexcess mortality rateMass screeningAgedPortugalPublic healthPublic Health Environmental and Occupational Healthmedicine.diseaseSpaincancer registriestrend analysisFollow-Up StudiesDemography
researchProduct

Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study

2016

Liver cancer represents a major clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from liver cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These tren…

MaleCancer ResearchDatabases FactualEpidemiologyTrends in survival0302 clinical medicineBelgiumCancer screeningMedicineCancer registries030212 general & internal medicineRegistriesYoung adultAged 80 and overmedicine.diagnostic_testMortality rateMedical recordLiver NeoplasmsMiddle Aged3. Good healthCancer registries; Europe; Excess mortality rate; Liver cancer; Net survival; Trends in survival;Survival RateEuropeOncologyItaly030220 oncology & carcinogenesisPopulation SurveillanceFemaleFranceLiver cancerLiver cancerSwitzerlandAdultAdolescentSocio-culturale03 medical and health sciencesYoung AdultNet survivalHumansAgedPortugalExcess mortality ratebusiness.industryPublic Health Environmental and Occupational Healthmedicine.diseaseCancer registrySpainLiver functionbusinessLiver function testsDemography
researchProduct

Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 coun…

2015

Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the eff ectiveness of health systems, and to inform global policy on cancer control. Methods Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15–99 years) and 75 000 children (age 0–14 years) diagnosed with cancer during 1995–2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardise…

Maleeurope 1999-2007PathologyCàncer -- EstadístiquesSurvival[SDV]Life Sciences [q-bio]2700 General MedicineGlobal HealthSettore MED/42 - Igiene Generale E ApplicataNeoplasms80 and overGlobal healthRegistriesStomach cancerChildcancer survivalBreast-cancerComputingMilieux_MISCELLANEOUScancer registry; cancer survival; worldwideCervical cancerAged 80 and overeducation.field_of_studychildhood-cancerMedicine (all)1. No povertyGeneral Medicinecancer survival; population-based registries; surveillanceMiddle Aged3. Good healthovarian-cancerChild Preschoolpopulation-based registriesurveillance/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalenet survivalNeoplasms/mortalityBreast-cancer; childhood-cancer; rectal-cancer; nordic countries; europe 1999-2007; ovarian-cancer; net survival; data quality; care; stageAdultmedicine.medical_specialtyAdolescentPopulationSocio-culturale610 Medicine & healthAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Child; Child Preschool; Female; Global Health; Humans; Infant; Infant Newborn; Male; Middle Aged; Neoplasms; Registries; Sex Distribution; Survival Analysis; Young Adult; Medicine (all)Articlerectal-cancerYoung AdultBreast cancerAge DistributionSDG 3 - Good Health and Well-beingcancer survival; cancer registriesmedicinedata qualityHumanscareSex DistributionPreschooleducationSupervivèncianordic countriesSurvival analysisddc:613AgedCancer -- Statisticsbusiness.industryInfant NewbornCancerInfant10060 Epidemiology Biostatistics and Prevention Institute (EBPI)Newbornmedicine.diseasestageSurvival AnalysisCancer registrycancer registriesbusinessDemography
researchProduct

Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status

2015

International audience; We aim to describe trends in net survival (NS) and to assess the prognostic factors among women with de novo metastatic breast cancer (MBC) according to human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status. Data on women suffering from de novo MBC and diagnosed from 1998 to 2009 were provided by the Côte-d'Or breast cancer registry. NS was described using the Pohar Perme estimator and prognostic factors were investigated in a generalised linear model. We identified 232 patients (mean age = 64.7). Median NS was 29.2 months, 1- and 5-year NS were 76% and 26% respectively. The survival trend in patients with HER2-positive tumours who did not …

Oncologymedicine.medical_specialtyReceptor ErbB-2Antineoplastic AgentsBreast NeoplasmsTriple Negative Breast NeoplasmsLower riskBreast cancerTrastuzumabInternal medicinemedicineHumansNeoplasm Metastasisskin and connective tissue diseasesAgedNeoplasm StagingGynecologyregisterbusiness.industryCarcinoma Ductal BreastAge FactorsAbsolute risk reductionhormone receptorsCancerTriple Negative Breast NeoplasmsMiddle AgedTrastuzumabHER2 receptorsPrognosismedicine.diseaseMetastatic breast cancerConfidence interval3. Good healthpopulation-basedCarcinoma LobularReceptors EstrogenOncologyLinear ModelsFemalemetastatic breast cancernet survivalReceptors Progesteronebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

Evaluation of the impact of therapeutic management on the survival and quality of life of patients with follicular lymphoma or diffuse large B cell l…

2014

In France, hematologic malignancies, which are the sixthmost common cancers, are amajor public healthproblem. This work aimed to study the impact of the therapeutic management on survival and healt-relatedquality of life (HRQoL) in patients with these hematologic malignancies. The first objective of this work is topresent an overview of the epidemiology of lymphoid malignancies with a study of changes in the incidenceand net survival in the Côte d’Or department between 1980 and 2009. The incidence, which has increased since1980, seems to have stabilized since the 2000s for some entities, including follicular lymphoma (FL) and diffuselarge B-cell lymphoma (DLBCL). Overall, we observed an imp…

Propensity scoreSurvie netteQualité de vie relative à la santéHealth-related quality of lifeIncidenceHémopathie lymphoïdeDiffuse large B-cell lymphomaLymphome folliculaireLymphome B diffus à grandes cellulesFollicular lymphomaNet survivalSurvie globale[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieScore de propensionHematologic malignanciesOverall survivalRituximab
researchProduct

A partial review of cure models with an application to French cancer registries data to improve patients' access to insurance and credit

2016

International audience; BackgroundSurvival cure models are widely used in public health researches to analyze time-to-event data in which some subjects would never experience the event of interest; these subjects are said to be statistically cured. There are two types of cure models, the mixture cure modeland the non-mixture cure model which were first formulated respectively by Boag(1949)[1] and Yakovlev et al. (1993) [2]. These models have been intensively developed [3,4 among others] and have also been extended to the net survival framework [5-7 for instance].In cancersurvival analysis,net survival is a measure of survival in the hypothetical world wherecancer would bethe only possible c…

[SDV.CAN] Life Sciences [q-bio]/Cancercancer registriesC ure rate modelscancer[SDV.CAN]Life Sciences [q-bio]/Cancernet survival[ SDV.CAN ] Life Sciences [q-bio]/Cancersurvival analysis
researchProduct

Geographical Disparities in Multiple Myeloma Survival in Three French Regions

2016

Abstract Introduction: Within the past decade, new therapeutic agents for Multiple Myeloma (MM) have improved survival of patients included in clinical trials. The aim of this study was to measure and compare characteristics and survival of patients with MM in different French regions in the general population. Methods: All incident cases with MM (ICD-O-3 codes, 9732/3 and) between January 1, 2008 and December 31, 2009 in the French population-based Hematological Malignancies registries (Calvados, Côte d'Or and Gironde) were included. The end point of follow-up was January 1, 2015. Specific clinical information was recorded from clinical charts. Incidence rates were calculated using estimat…

education.field_of_studyPediatricsmedicine.medical_specialtyMultivariate analysisAnemiabusiness.industryImmunologyPopulationImproved survivalCell BiologyHematologymedicine.diseaseBiochemistryClinical trialmedicinebusinesseducationNet SurvivalSex ratioMultiple myelomaDemographyBlood
researchProduct